Recombinant Human Protein capicua homolog (CIC), partial

1. Fluorescence in situ hybridization and targeted next-generation sequencing identified a CIC-NUTM1 fusion resulting from t(15;19)(q14;q13.2). In light of morphologic features that overlap with those of NC from typical anatomical sites we have seen previously, the tumor was best classified as falling within the NC spectrum rather than CIC-associated sarcoma. PMID: 29700887
2. Case Report: t(10;19) CIC-DUX4 undifferentiated small round cell sarcoma of the abdominal wall. PMID: 28645808
3. Results indicate an important role for transcriptional repression factor Capicua (CIC) in regulating neural cell proliferation and lineage specification, and suggest that CIC mutations may impact the pathogenesis and therapeutic targeting of oligodendroglioma. PMID: 28939681
4. The ATXN1L-CIC-ETS transcription factor axis as a mediator of resistance to MAPKi. PMID: 28178529
5. CIC deficiency was associated with disruptions in the expression of genes involved in cell-cell adhesion, and in the development of several cell and tissue types. We also showed that loss of CIC leads to overexpression of downstream members of the mitogen-activated protein kinase (MAPK) signalling cascade, indicating that CIC deficiency may present a novel mechanism for activation of this oncogenic pathway. PMID: 28295365
6. Case Report: genetically distinct variant of CIC-rearranged sarcomas with a novel NUTM2A-CIC fusion. PMID: 28188754
7. Findings show CIC-DUX4 sarcomas occur mostly in young adults within the somatic soft tissues, having a wide spectrum of morphology including round, epithelioid and spindle cells, and associated with an aggressive clinical course, with an inferior survival compared with Ewing sarcoma. Results support classification of CIC-rearranged tumors as an independent molecular and clinical subset of small blue round cell tumors. PMID: 28346326
8. Capicua underexpression is associated with lung cancer metastasis. PMID: 27869830
9. Targeted next-generation sequencing of CIC-DUX4 soft tissue sarcomas demonstrates low mutational burden and recurrent chromosome 1p loss. PMID: 27664537
10. Data indicate that the HMG-box of Capicua (CIC) does not bind DNA alone but instead requires a distant motif (referred to as C1) present at the C-terminus of all CIC proteins. PMID: 28278156
11. The aim of this study was to describe seven cases of CIC-DUX4 fusion-positive sarcomas, including the first reported example arising primarily in bone. Our series confirms that CIC-DUX4 fusion-positive sarcomas are aggressive tumours with an adverse prognosis PMID: 27079694
12. analysis of homozygous deletions of 19q13.2 and CIC in neuroblastoma PMID: 26794043
13. Report CIC genetic alterations in angiosarcomas. PMID: 26735859
14. With the advent of large-scale genome sequencing technology, molecular genetic alterations in CIC promoter have now been identified in the majority of oligodendrogliomas PMID: 26545048
15. miR-93/miR-106b/miR-375-CIC-CRABP1 is a novel key regulatory axis in prostate cancer progression PMID: 26124181
16. CIC-rearranged sarcomas are distinct from Ewing sarcomas clinically, morphologically, and immunohistochemically, and they should be considered a separate entity rather than being grouped within the same family of tumors. PMID: 26685084
17. CIC mutations result in protein inactivation and poorer outcome in patients with a 1p19q codeleted glioma. PMID: 26017892
18. Our study showed for the first time a cooperative reduction in clonogenicity in cells co-expressing IDH1-R132H and mutant CIC proteins PMID: 25277207
19. It is a supportive diagnostic marker for oligodendroglial tumors with the 1p/19q co-deletion. PMID: 24197863
20. Case Report: CIC-FOXO4 fusion sarcoma is a new type of Ewing-like sarcoma that has a specific genetic signature. PMID: 25007147
21. The distinct gene signature and immunoprofile of CIC-DUX4 sarcomas suggest a distinct pathogenesis from Ewing sarcoma. PMID: 24723486
22. We conclude that absent CIC and FUBP1 expressions are potential markers of shorter time to recurrence in oligodendroglial tumors. PMID: 24030748
23. Downregulation of CIC protein levels was not associated with ETV1 or pMEK1/2 expression, KIT and PDGFRA mutations, copy number variations (CNV) of 19q13, and clinical factors. PMID: 24897389
24. CIC acts as a tumor suppressor in these tumors, whereas FUBP1 might play only a minor role PMID: 24086756
25. Analysis allowed us to define two highly recurrent genetic signatures in gliomas: IDH1/ATRX (I-A) and IDH1/CIC/FUBP1 (I-CF). PMID: 22869205
26. Found CIC and FUBP1 mutations in oligodendrogliomas and demonstrate the presence of these mutations in oligoastrocytomas. PMID: 22588899
27. Our detailed study of genetic aberrations in oligodendroglioma suggests a functional interaction between CIC mutation, IDH1/2 mutation, and 1p/19q co-deletion PMID: 22072542
28. CIC gene was mutated in 6 oligodendrogliomas and FUBP1 gene was mutated in 2; 27 additional oligodendrogliomas showed 12 and 3 more tumors with mutations of CIC and FUBP1; results suggest role of these genes in biology and pathology of oligodendrocytes PMID: 21817013
29. human capicua represses mRNA expression for PEA3 (polyoma enhancer activator 3) Ets transcription factors ETV1, ETV4 and ETV5 PMID: 21087211
30. Results describe the identification and characterization of a new gene, Cic, in both human and mouse genomes, that is implicated in granule cell development. PMID: 12393275
31. Medulloblastomas exhibited the highest level of CIC expression, although the level of expression varied between different medulloblastoma subtypes. Expression was most common in tumors of the CNS in general. PMID: 15981098

Show More

Hide All

HGNC: 14214

OMIM: 612082

KEGG: hsa:23152

STRING: 9606.ENSP00000160740

UniGene: Hs.388236